Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: Effects on circulating markers of inflammation from the MARINE and ANCHOR studies

American Journal of Cardiovascular Drugs

Volumn 13, Issue 1, 2013, Pages 37-46

  Bays, Harold E ^a   Ballantyne, Christie M ^b   Braeckman, Rene A ^c   Stirtan, William G ^c   Soni, Paresh N ^c  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Amarin Pharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID ETHYL ESTER; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE 2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFECT; DRUG USE; HUMAN; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; ESTERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84874052886     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-012-0002-3     Document Type: Article

References (38)

1. Libby P, Okamoto Y, Rocha VZ, et al. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74(2):213-20.
2. Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5:338-67.
3. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997;96(12):4219-25.
4. Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep. 2009;61(1):22-32.
5. Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal. 2010;13(1):39-75.
6. Meisinger C, Baumert J, Khuseyinova N, et al. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation. 2005;112(5):651-7.
7. Toth PP, McCullough PA, Wegner MS, et al. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker. Expert Rev Cardiovasc Ther. 2010;8(3):425-38.
8. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008;101(12A):41F-50F.
9. Schuett H, Luchtefeld M, Grothusen C, et al. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009;102(2):215-22.
10. Nystrom T. C-reactive protein: a marker or a player? Clin Sci (Lond) 2007;113(2):79-81.
11. Bays HE. Adiposopathy is "sick fat" a cardiovascular disease? J Am Coll Cardiol. 2011;57(25):2461-73.
12. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109(7):837-42.
13. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005;165(21):2479-84.
14. Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007;99(6A):35C-43C.
15. Bays H. Fish oils in the treatment of dyslipidemia and cardiovascular disease. In: Kwiterovich PO, editor. The Johns Hopkins textbook of dyslipidemia. Philadelphia: Lippincott Williams & Wolters Kluwer; 2010. p. 245-57.
16. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108(5):682-90.
17. Ballantyne CM, Bays HE, Kastelein JJ, et al. A phase 3, multicenter, placebo-controlled, randomized, double-blind, 12-week study to evaluate the effect of two doses of AMR101 on fasting serum triglycerides and other lipid parameters in statin-treated patients with persistent high triglycerides (≥200 and <500 mg/dL): the ANCHOR study. Am J Cardiol. 2012;110(7):984-92.
18. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959-65.
19. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207.
20. Garrido-Sanchez L, Garcia-Fuentes E, Rojo-Martinez G, et al. Inverse relation between levels of anti-oxidized-LDL antibodies and eicosapentanoic acid (EPA). Br J Nutr. 2008;100(3):585-9.
21. Mesa MD, Buckley R, Minihane AM, et al. Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of low-density lipoprotein. Atherosclerosis. 2004;175(2):333-43.
22. Watanabe E, Sobue Y, Sano K, et al. Eicosapentaenoic acid for the prevention of recurrent atrial fibrillation. Ann Noninvasive Electrocardiol. 2011;16(4):373-8.
23. Mori TA, Woodman RJ, Burke V, et al. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med. 2003;35(7):772-81.
24. Satoh N, Shimatsu A, Kotani K, et al. Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens Res. 2009;32(11):1004-8.
25. Satoh N, Shimatsu A, Kotani K, et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care. 2007;30(1):144-6.
26. Kelley DS, Siegel D, Fedor DM, et al. DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr. 2009;139(3):495-501.
27. Micallef MA, Munro IA, Garg ML. An inverse relationship between plasma n-3 fatty acids and C-reactive protein in healthy individuals. Eur J Clin Nutr. 2009;63(9):1154-6.
28. Bloomer RJ, Larson DE, Fisher-Wellman KH, et al. Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study. Lipids Health Dis. 2009;8:36.
29. Chan DC, Watts GF, Barrett PH, et al. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem. 2002;48(6 Pt 1):877-83.
30. Skulas-Ray AC, Kris-Etherton PM, Harris WS, et al. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr. 2011;93(2):243-52.
31. Pedersen MW, Koenig W, Christensen JH, et al. The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr. 2009;48(1):1-5.
32. Nelson TL, Hokanson JE, Hickey MS. Omega-3 fatty acids and lipoprotein associated phospholipase A(2) in healthy older adult males and females. Eur J Nutr. 2011;50(3):185-93.
33. Davidson MH, Maki KC, Bays H, et al. Effects of prescription omega-3 ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol. 2009;3(5):332-40.
34. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104(4):503-16.
35. Bays HE, Tighe AP, Sadovsky R, et al. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6(3):391-409.
36. Bays H. Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians. Drugs Today (Barc). 2008;44(3):205-46.
37. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090-8.
38. Itakura H, Yokoyama M, Matsuzaki M, et al. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb. 2011;18(2):99-107.